[go: up one dir, main page]

FR23C1003I1 - Compositions et leurs utilisations pour le traitement de la Sclérose en plaques - Google Patents

Compositions et leurs utilisations pour le traitement de la Sclérose en plaques

Info

Publication number
FR23C1003I1
FR23C1003I1 FR23C1003C FR23C1003C FR23C1003I1 FR 23C1003 I1 FR23C1003 I1 FR 23C1003I1 FR 23C1003 C FR23C1003 C FR 23C1003C FR 23C1003 C FR23C1003 C FR 23C1003C FR 23C1003 I1 FR23C1003 I1 FR 23C1003I1
Authority
FR
France
Prior art keywords
compositions
treatment
multiple sclerosis
sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1003C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39682314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1003(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of FR23C1003I1 publication Critical patent/FR23C1003I1/fr
Application granted granted Critical
Publication of FR23C1003I2 publication Critical patent/FR23C1003I2/fr
Active legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
FR23C1003C 2007-02-08 2023-01-12 Compositions et leurs utilisations pour le traitement de la Sclérose en plaques Active FR23C1003I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88892107P 2007-02-08 2007-02-08
EP08725256.5A EP2137537B8 (fr) 2007-02-08 2008-02-07 Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
PCT/US2008/001602 WO2008097596A2 (fr) 2007-02-08 2008-02-07 Essais de criblage de nrf2 et procédés et compositions correspondants

Publications (2)

Publication Number Publication Date
FR23C1003I1 true FR23C1003I1 (fr) 2023-03-10
FR23C1003I2 FR23C1003I2 (fr) 2024-01-12

Family

ID=39682314

Family Applications (2)

Application Number Title Priority Date Filing Date
FR14C0050C Active FR14C0050I1 (fr) 2007-02-08 2014-06-25 Compositions et leurs utilisations pour le traitement de la sclerose en plaques
FR23C1003C Active FR23C1003I2 (fr) 2007-02-08 2023-01-12 Compositions et leurs utilisations pour le traitement de la Sclérose en plaques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR14C0050C Active FR14C0050I1 (fr) 2007-02-08 2014-06-25 Compositions et leurs utilisations pour le traitement de la sclerose en plaques

Country Status (19)

Country Link
US (8) US20110112196A1 (fr)
EP (10) EP2680008A1 (fr)
CY (4) CY1114340T1 (fr)
DE (2) DE13169139T1 (fr)
DK (3) DK2653873T3 (fr)
ES (3) ES2916649T3 (fr)
FI (2) FI2629097T1 (fr)
FR (2) FR14C0050I1 (fr)
HK (1) HK1139204A1 (fr)
HR (2) HRP20220902T3 (fr)
HU (1) HUS2300001I1 (fr)
LT (2) LT2653873T (fr)
LU (1) LU92487I2 (fr)
NO (2) NO2014015I1 (fr)
PL (2) PL2653873T3 (fr)
PT (2) PT2137537E (fr)
RS (2) RS63489B1 (fr)
SI (2) SI2137537T1 (fr)
WO (1) WO2008097596A2 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US20070027076A1 (en) 2003-09-09 2007-02-01 Fumapham Ag Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
LT1799196T (lt) * 2004-10-08 2016-09-12 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinė kompozicija, apimanti fumaro rūgšties esterį
EP2680008A1 (fr) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Essais de criblage de Nrf2 et procédés et compositions correspondants
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
SI2252283T1 (sl) 2008-01-11 2019-02-28 Reata Pharmaceuticals, Inc. Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
EP2271658B1 (fr) 2008-04-18 2016-11-09 Reata Pharmaceuticals, Inc. Modulateurs d'inflammation antioxydants : dérivés d'acide oléanolique c-17 homologués
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010022177A2 (fr) 2008-08-19 2010-02-25 Xenoport, Inc. Promédicaments de fumarate de méthyle-hydrogène, compositions pharmaceutiques à base de ceux-ci, et procédés d'utilisation
PT2379063E (pt) 2009-01-09 2013-05-03 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
CN102427727A (zh) * 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
NZ601698A (en) 2010-01-08 2015-04-24 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
CA2789950C (fr) 2010-02-18 2018-09-04 High Point Pharmaceuticals, Llc Derives d'imidazole fusionnes et substitues, compositions pharmaceutiques et procedes d'utilisation associes
EP2648732A4 (fr) * 2010-12-07 2014-04-30 Teva Pharma Utilisation de laquinimod pour la réduction de la fatigue, l'amélioration de l'état fonctionnel, et l'amélioration de la qualité de vie chez des patients atteints de sclérose en plaques
SMT201800069T1 (it) 2010-12-17 2018-03-08 Reata Pharmaceuticals Inc Pirazolil- e pirimidinilenoni triciclici quali modulatori d'infiammazione antiossidanti
HUE044081T2 (hu) 2011-03-11 2019-09-30 Reata Pharmaceuticals Inc C4 Monometil-triterpenoid-származékok, és módszerek azok alkalmazására
WO2012145420A1 (fr) * 2011-04-18 2012-10-26 Rutgers, The State University Of New Jersey Composition, procédé de synthèse et utilisation de nouveaux modulateurs d'inflammation antioxydants
CA2865316A1 (fr) * 2011-04-28 2012-11-01 Gino Cortopassi Agents utiles pour le traitement de l'ataxie de friedreich et autres maladies neurodegeneratives
WO2012162669A1 (fr) * 2011-05-26 2012-11-29 Biogen Idec Ma Inc. Méthodes de traitement de la sclérose en plaques et de conservation et/ou d'augmentation de la teneur en myéline
BR112013031616A2 (pt) 2011-06-08 2016-12-06 Biogen Idec Inc processo para preparar fumarato de dimetila de alta pureza e cristalino
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
US9421273B2 (en) 2011-12-16 2016-08-23 Biogen Ma Inc. Silicon-containing fumaric acid esters
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
JP6283346B2 (ja) * 2012-03-30 2018-02-21 ネステク ソシエテ アノニム ４−オキソ−２−ペンテン酸及び脳の健康
SI2841445T1 (sl) 2012-04-27 2017-12-29 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamidni derivati bardoksolon metila, njihove polimorfne oblike in postopki za njihovo uporabo
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
EP2887934A1 (fr) 2012-08-22 2015-07-01 XenoPort, Inc. Méthodes d'administration du monométhyl fumarate et des promédicaments associés présentant des effets secondaires réduits
JP2015526477A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
AU2013312106B2 (en) 2012-09-10 2018-03-08 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
WO2014058982A2 (fr) * 2012-10-10 2014-04-17 Temple University Of The Commonwealth System Of Higher Education Biocapteurs de facteur nucléaire 2 apparenté au facteur érythroïde 2 (nrf2) et modulateurs de nrf2
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
WO2014100728A1 (fr) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Dérivés de fumarate substitués par du deutérium
WO2014138298A1 (fr) * 2013-03-05 2014-09-12 University Of Chicago Traitement de troubles de démyélinisation
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
NZ737435A (en) 2013-03-14 2019-02-22 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (fr) * 2013-03-24 2014-10-02 Xenoport, Inc. Compositions pharmaceutiques de fumarate de diméthyle
WO2014197860A1 (fr) 2013-06-07 2014-12-11 Xenoport, Inc. Procédé de production de monométhylfumarate
WO2014205392A1 (fr) 2013-06-21 2014-12-24 Xenoport, Inc. Co-cristaux de diméthyl fumarate
ES2526979B1 (es) * 2013-07-17 2015-10-28 Fundación Para La Investigación Biomédica Del Hospital Universitario De La Princesa Uso del 3-(2-isotiocianatoetil)-5-metoxi-1H-indol para el tratamiento de enfermedades neurodegenerativas
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
WO2015066190A1 (fr) 2013-10-29 2015-05-07 President And Fellows Of Harvard College Procédés et compositions pour inhiber le stress oxydatif
CN103768045B (zh) * 2013-10-30 2015-10-07 苏州大学附属第一医院 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
EP3110793B1 (fr) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamide et promédicaments de fumarates de sulfinamide et leur utilisation dans le traitement de diverses maladies
EP3766487A1 (fr) 2014-02-28 2021-01-20 Banner Life Sciences LLC Capsules entériques molles à libération contrôlée d'esters de fumarate
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP2924127A1 (fr) * 2014-03-27 2015-09-30 Université Paul Sabatier Toulouse III Procédé et kit pour le pronostic des maladies induites par une défaillance du gène OPA1, telle que l'atrophie optique
UY36099A (es) 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
DE102014010832A1 (de) 2014-07-24 2016-01-28 Peter Krause Verwendung von medikamentösen Ingredienzien zur Behandlung von Multiple Sklerose
WO2016089648A1 (fr) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
MA41785A (fr) * 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
WO2016160635A1 (fr) 2015-03-27 2016-10-06 Sytheon Limited Compositions et procédés de traitement du psoriasis
US10085961B2 (en) 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN105087644A (zh) * 2015-07-23 2015-11-25 山东大学 一种高通量筛选具有Nrf2激活活性的化合物的方法
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
US11584775B2 (en) 2015-09-23 2023-02-21 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2018093591A1 (fr) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
JP7379164B2 (ja) 2017-06-02 2023-11-14 ジュノー セラピューティクス インコーポレイテッド 細胞療法に関連する毒性に関する製造物品および方法
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
WO2019079242A1 (fr) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Traitement de la sclérose latérale amyotrophique (sla)
WO2019089848A1 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés associés à une charge tumorale pour évaluer une réponse à une thérapie cellulaire
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
WO2020010035A1 (fr) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Système de canule
CN112567035A (zh) 2018-07-02 2021-03-26 沃雅戈治疗公司 肌萎缩侧索硬化症及脊髓相关病症的治疗
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
EP4393547A3 (fr) 2018-11-30 2024-09-18 Juno Therapeutics, Inc. Procédés de dosage et de traitement de tumeurs malignes de lymphocytes b dans une thérapie cellulaire adoptive
EP4427810A3 (fr) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Procédés de traitement utilisant une thérapie cellulaire adoptive
US20230053787A1 (en) 2019-12-06 2023-02-23 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4117785A4 (fr) * 2020-03-13 2024-04-17 Marc J. Simard Méthodes de traitement de la sclérose en plaques

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
JPS5824104B2 (ja) 1977-12-06 1983-05-19 博衛 小川 フマル酸製剤
DE2840498C2 (de) 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
DE3127432A1 (de) 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
US5149695A (en) 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61194020A (ja) 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
US4855305A (en) 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5242905A (en) 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
AU1271592A (en) 1991-01-18 1992-08-27 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5459667A (en) 1993-01-22 1995-10-17 Sumitomo Electric Industries, Ltd. Navigation apparatus for informing vehicle driver of information regarding travel route
CA2164837A1 (fr) 1993-06-08 1994-12-22 Raymond K. Brown Compositions therapeutiques et methodes d'utilisation
JPH06345644A (ja) 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
US5407772A (en) 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
DE69521122T2 (de) 1994-03-16 2002-03-07 Cenes Ltd., Cambridge 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
US6649143B1 (en) 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5763190A (en) 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CN1125141A (zh) 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
JP2535141B2 (ja) 1995-01-17 1996-09-18 中外製薬株式会社 フマル酸含有徐放性製剤
CA2226915A1 (fr) 1995-09-13 1997-03-20 Yoshikazu Ohta Agent immunosuppresseur
EP0852233A4 (fr) 1995-09-21 1999-09-15 Nippon Shinyaku Co Ltd Derives de phosphates de cyclosporine et composition medicinale
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
JP4004567B2 (ja) 1996-02-14 2007-11-07 アステラス製薬株式会社 Ｗｂ２６６３ｂ物質を含有する免疫抑制剤
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
CZ378998A3 (cs) 1996-05-22 1999-07-14 University Of Alberta Vázací proteiny chemokinu typ-2 a způsoby jejich využití
WO1997048405A1 (fr) 1996-06-21 1997-12-24 Jury Evgenievich Belyaev Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes
EP0969869A2 (fr) 1996-07-26 2000-01-12 Susan P. Perrine Compositions contenant un agent inducteur ainsi qu'un agent antiviral et destinees au traitement de troubles cellulaires, sanguins et viraux
WO1998027970A2 (fr) 1996-12-24 1998-07-02 National Research Council Of Canada Traitement de maladies ou prevention de dommages cellulaires causes par des radicaux libres contenant de l'oxygene
US5972363A (en) 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
AU760140B2 (en) 1997-10-24 2003-05-08 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US20050245612A1 (en) 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
WO2001059072A1 (fr) 2000-02-11 2001-08-16 Philadelphia Health And Education Corporation Differentiation des cellules stromales de la moelle osseuse en cellules neuronales et utilisation associee
US6812248B2 (en) 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
AU2002230423A1 (en) 2000-11-08 2002-05-21 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
US6451667B1 (en) 2000-12-21 2002-09-17 Infineon Technologies Ag Self-aligned double-sided vertical MIMcap
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
ME00135B (fr) 2001-01-12 2012-06-03 Fumapharm Ag Amides de l'acide fumarique
RU2301665C2 (ru) 2001-02-14 2007-06-27 Маттиас Рат Композиции биохимических соединений, участвующих в биоэнергетическом метаболизме клетки, и способ их применения
RU2189813C1 (ru) 2001-06-01 2002-09-27 Российский научно-исследовательский институт гематологии и трансфузиологии Лекарственное средство антигипоксического действия
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
WO2003032969A2 (fr) 2001-10-15 2003-04-24 National Research Council Of Canada Agents anti-glycation destines a la prevention des complications liees a l'age, au diabete et au tabagisme
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US20070027076A1 (en) 2003-09-09 2007-02-01 Fumapham Ag Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
LT1799196T (lt) 2004-10-08 2016-09-12 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinė kompozicija, apimanti fumaro rūgšties esterį
EP1812374A1 (fr) 2004-11-10 2007-08-01 Aditech Pharma AB Nouveaux sels de monoalkylesters d'acide fumarique et leur utilisation pharmaceutique
WO2006055871A2 (fr) 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Traitement de la sclerose en plaques
US7638119B2 (en) 2004-12-02 2009-12-29 Wisconsin Alumni Research Foundation Method of diminishing the symptoms of neurodegenerative disease
EP1674082A1 (fr) 2004-12-22 2006-06-28 Zentaris GmbH Procédé pour la manufacture des suspensions ou lyophilisates steriles des complexes mal-soluble de peptides basic, des formulations pharmaceutiques avec ces complexes et leur utilisation comme medicament
JP2008530212A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有するピペラジン−ピペリジン
AU2006216941B2 (en) 2005-02-16 2009-12-03 Pharmacopeia, Llc Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
CN101142209A (zh) 2005-02-16 2008-03-12 先灵公司 具有cxcr3拮抗剂活性的吡嗪基取代的哌嗪-哌啶
US7417045B2 (en) 2005-02-16 2008-08-26 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
EP1853583B1 (fr) 2005-02-16 2011-09-07 Schering Corporation Pyridyle a liaison amine et piperazine-piperidines substituees a activite agoniste cxcr3
KR20070107056A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ３ 길항제 활성을 지닌 피리딜 및 페닐 치환된피페라진-피페리딘
PE20061093A1 (es) 2005-02-16 2006-11-10 Schering Corp Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3
DE102005022845A1 (de) 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
CA2614110A1 (fr) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions et procedes pour traiter ou prevenir des troubles associes au stress oxydatif
WO2007006307A2 (fr) 2005-07-07 2007-01-18 Aditech Pharma Ab Nouveaux sels de monoalkylesters d'acide fumarique et leur utilisation pharmaceutique
US20100144651A1 (en) 2005-07-07 2010-06-10 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
US20080299196A1 (en) 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
EP1940382A2 (fr) 2005-10-07 2008-07-09 Aditech Pharma AB Polytherapie a base d' esters d' acide fumarique pour le traitement de maladies autoimmunes et/ou inflammatoires
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
EP2680008A1 (fr) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Essais de criblage de Nrf2 et procédés et compositions correspondants
HUE032251T2 (en) 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
CN102427727A (zh) 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
ME02317B (me) 2010-02-12 2016-06-20 Biogen Ma Inc Neuroprotekcija kod demijelinizacijskih bolesti
JP2013221921A (ja) 2012-04-19 2013-10-28 Heidenhain Kk ロータリーエンコーダ

Also Published As

Publication number Publication date
EP2680007A1 (fr) 2014-01-01
US20150366803A1 (en) 2015-12-24
HRP20220902T3 (hr) 2022-10-14
CY2014026I2 (el) 2016-10-05
PL2653873T1 (pl) 2022-07-04
FI2629097T1 (fi) 2022-06-15
CY2014026I1 (el) 2016-10-05
NO2014015I1 (no) 2014-06-26
US20200016072A1 (en) 2020-01-16
SI2137537T1 (sl) 2013-10-30
NO2023001I1 (no) 2023-01-02
ES2916604T1 (es) 2022-07-04
LT2653873T (lt) 2022-10-10
SI2653873T1 (sl) 2022-09-30
CY2023002I1 (el) 2023-06-09
PL2137537T3 (pl) 2013-10-31
EP2653873A1 (fr) 2013-10-23
RS52922B (en) 2014-02-28
RS63489B1 (sr) 2022-09-30
PT2653873T (pt) 2022-07-26
WO2008097596A2 (fr) 2008-08-14
ES2916649T3 (es) 2022-09-21
EP2653873B8 (fr) 2022-08-24
US20110112196A1 (en) 2011-05-12
HK1139204A1 (en) 2010-09-10
WO2008097596A3 (fr) 2008-12-11
PT2137537E (pt) 2013-08-22
US20120196931A1 (en) 2012-08-02
CY2023004I1 (el) 2023-06-09
US20130303613A1 (en) 2013-11-14
EP2137537B1 (fr) 2013-05-29
EP2653873B1 (fr) 2022-07-20
US20120259012A1 (en) 2012-10-11
EP2137537B8 (fr) 2016-06-01
LU92487I2 (fr) 2015-11-02
FR14C0050I1 (fr) 2014-08-08
US20130317103A1 (en) 2013-11-28
EP4137819A1 (fr) 2023-02-22
EP2680009A1 (fr) 2014-01-01
ES2916649T1 (es) 2022-07-04
CY2023004I2 (el) 2023-06-09
DK2653873T1 (da) 2022-05-30
EP2680010A1 (fr) 2014-01-01
FR23C1003I2 (fr) 2024-01-12
EP2680006A1 (fr) 2014-01-01
HUS2300001I1 (hu) 2023-02-28
ES2424022T3 (es) 2013-09-26
DK2137537T3 (da) 2013-07-29
LTPA2023503I1 (fr) 2023-02-10
DK2629097T1 (da) 2022-05-30
PL2653873T3 (pl) 2022-08-22
HRP20130707T1 (en) 2013-09-30
DE13169139T1 (de) 2022-07-14
EP2137537A2 (fr) 2009-12-30
EP2518511A1 (fr) 2012-10-31
EP2680008A1 (fr) 2014-01-01
EP2629097A1 (fr) 2013-08-21
DE13156663T1 (de) 2022-07-14
CY1114340T1 (el) 2016-08-31
DK2653873T3 (da) 2022-07-25
US8399514B2 (en) 2013-03-19
FIC20230002I1 (fi) 2023-01-16
US20180263906A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
FR23C1003I2 (fr) Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
EP2322221A4 (fr) Composition pharmaceutique pour le traitement et la prévention du cancer
EP2542060A4 (fr) Compositions et méthodes pour le traitement et/ou la prévention de maladies cardio-vasculaires
EP2224955A4 (fr) Compositions et procédés pour la prévention et le traitement de l'arthrite
EP2338519A4 (fr) Agent de traitement d'une myélofibrose
EP2532680A4 (fr) Composition médicinale pour le traitement et/ou la prévention du cancer
EP2552203A4 (fr) Composés et compositions pharmaceutiques pour le traitement d'infections virales
EP2554175A4 (fr) Composition pour le traitement d'une partie lésée
EP2651407A4 (fr) 3-méthanesulfonylpropionitrile pour le traitement d'une inflammation et de la douleur
EP2352517A4 (fr) Procédés et compositions pour le traitement de troubles associés au complément
EP2804669A4 (fr) Compositions et procédés d'utilisation d'esters de phorbol pour le traitement de l'avc
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
EP2568999A4 (fr) Acth pour le traitement de la sclérose latérale amyotrophique
EP2558466A4 (fr) Phosphonates présentant une toxicité réduite pour le traitement d'infections virales
EP2367798A4 (fr) Traitement de la sclérose latérale amyotrophique
EP2558085A4 (fr) Compositions et procédés pour la prévention et le traitement du cancer
EP2307035A4 (fr) Traitement de l'épilepsie
EP2203057A4 (fr) Procédés et compositions pour le traitement ou la prévention d'états inflammatoires
EP2192920A4 (fr) Procédés et compositions pour le traitement ou la prévention d'une fibrose induite par rayonnement
EP2632452A4 (fr) Composés et compositions pour le traitement du cancer
EP2376091A4 (fr) Nouvelles cibles pour le traitement de l'hypercholestérolémie
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
EP2498792A4 (fr) Procédés et compositions pour le traitement rapide d'une otite externe
EP2437738A4 (fr) Procédés et compositions pour le traitement du cancer
EP2536436A4 (fr) Antimir-451 pour le traitement de polycythémies